- Home
- BIAF vs ADIL Comparison
BIAF vs ADIL Comparison
Compare BIAF & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | ADIL |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.4M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BIAF | ADIL |
|---|---|---|
| Price | $1.37 | $0.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 80.0K | ★ 347.3K |
| Earning Date | 11-14-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,776,739.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.11 | $0.21 |
| 52 Week High | $46.53 | $1.30 |
Technical Indicators
Market Signals| Indicator | BIAF | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 42.05 |
| Support Level | $1.26 | $0.21 |
| Resistance Level | $1.44 | $0.24 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 58.30 | 33.39 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.